BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Deals

  EMD Serono Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

  Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD).

  December 20, 2021

   · 

  3 min read
• FDA

  FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL

  Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

  December 20, 2021

   · 

  18 min read
• Pharm Country

  Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 20, 2021

  Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that, effective December 16, 2021, its independent directors approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to two individuals entering into employment with the Company.

  December 20, 2021

   · 

  2 min read